PN injection benefit restriction suddenly halted
By Nho, Byung Chul | translator Kim, Jung-Ju
23.11.07 12:10:53
°¡³ª´Ù¶ó
0
Manufacturers of PN ingredient intraarticular injections recently submitted opinions to the HIRA
Re-discussion of the one-time benefit limit over the life cycle and the presentation/notification
Process to the health policy deliberation committee is also expected to be postponed
¡ãIntra-articular injection of PN ingredients reduces knee cartilage friction by maintaining physical restoration and high elasticity
With the advent of the reevaluation period for selective coverage of intraarticular injections containing PN (sodium polynucleotide), health authorities are planning to adjust the patient copayment upward. Manufacturers and sellers have recently submitted opinions to HIRA, drawing attention to the future direction. The opinion is based on supporting papers and clinical evaluations, and it is expected that the issue of 'restrictions on reimbursement of related products' will be quickly resolved. According to the industry on the 7th, HIRA held a suitability evaluation committee and treatment material expert evaluation committee from early this year to September with the advent of the selective reimbursement period for
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)